ABSTRACT

Introduction: although tuberculosis is preventable and curable, this infection represents the leading cause of death from a single infectious agent. The interruption of public health services caused by the COVID-19 pandemic globally reversed the gradual progress that had been achieved in reducing mortality and the incidence of drug-resistant tuberculosis has not been completely determined. Objective: to determine the presence of comorbidities and their association with antimicrobial resistance in tuberculosis in 2022. Material and methods: a total of 480 cases diagnosed through molecular diagnosis (PCR), microbiological culture, M. tuberculosis isolation, and drug susceptibility testing, reported by UIBMZ-IMSS in the epidemiological surveillance laboratory during the period from January to December 2022. Results: a total of 480 tuberculosis cases diagnosed in Mexico in 2022 were analyzed, with 46.88% showing antimicrobial resistance. The most common resistance was to streptomycin (11.67%), followed by pyrazinamide (6.46%), while resistance to isoniazid and ethambutol was lower. It was found that 5.63% of the cases showed resistance to more than three drugs. Resistant tuberculosis was associated with comorbidities such as immunosuppression and drug use. Conclusions: the present study emphasizes the need to adjust health policies to control drug- resistant tuberculosis, focused on vulnerable populations, mainly immunosuppressed people, or people with addictions.

KEYWORDS

tuberculosis, incidence, Mycobacterium tuberculosis, multidrug-resistance, comorbidity.

REFERENCES

1. Cardona PJ. Pathogenesis of tuberculosis and other mycobacteriosis.Enferm Infecc Microbiol Clin (Engl Ed). 2018;36(1):38-46. doi:10.1016/j.eimc.2017.10.015.

2. World Health Organization. Global tuberculosis report 2023 [Internet].Geneva: World Health Organization; 2023. Available in: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/globaltuberculosis-report-2023

3. World Health Organization. COVID-19 and tuberculosis [Internet].Geneva: World Health Organization; 2022. Available in: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2022/covid-19-and-tb

4. Secretaría de Salud, Gobierno de México. Boletín epidemiológico,Sistema Nacional de Vigilancia Epidemiológica, Sistema Únicode Información, 2021 [Internet]. Ciudad de México: Secretaríade Salud; 2021. Disponible en: https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema-nacional-de-vigilanciaepidemiologica-sistema-unico-de-informacion-2021

5. Caminero JA, García-García JM, Cayla JA, García-Pérez FJ, PalaciosJJ, Ruiz-Manzano J. Update of SEPAR guideline «Diagnosis andTreatment of Drug-Resistant Tuberculosis». Arch Bronconeumol(Engl Ed). 2020;56(8):514-521. doi: 10.1016/j.arbres.2020.03.021.

6. Instituto Nacional de Salud Pública. Sí, podemos poner fin a latuberculosis [Internet]. Cuernavaca: Instituto Nacional de SaludPública; 2023. Disponible en: https://www.insp.mx/avisos/sipodemos-poner-fin-a-la-tuberculosis

7. Abubakar I, Crofts JP, Gelb D, Story A, Andrews N, Watson JM.Investigating urban-rural disparities in tuberculosis treatment outcomein England and Wales. Epidemiol Infect. 2008;136(1):122-127. doi:10.1017/s0950268807008333.

8. Woldesemayat EM. Tuberculosis in migrants is among the challengesof tuberculosis control in high-income countries. Risk Manag HealthcPolicy. 2021;14:2965-2970. doi: 10.2147/rmhp.s314777.

9. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors fortuberculosis. Pulm Med. 2013;2013:828939. doi: 10.1155/2013/828939